Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
ERRγ suppression by Sirt6 alleviates cholestatic liver injury and fibrosis
Lihua Hao, … , Eun Ju Bae, Byung-Hyun Park
Lihua Hao, … , Eun Ju Bae, Byung-Hyun Park
Published July 23, 2020
Citation Information: JCI Insight. 2020;5(17):e137566. https://doi.org/10.1172/jci.insight.137566.
View: Text | PDF
Research Article Hepatology Metabolism

ERRγ suppression by Sirt6 alleviates cholestatic liver injury and fibrosis

  • Text
  • PDF
Abstract

Orphan nuclear receptor estrogen-related receptor γ (ERRγ) stimulates bile acid production; however, the role and the regulatory mechanism of ERRγ in cholestatic liver disease are largely unknown. This study identifies that Sirt6 is a deacetylase of ERRγ and suggests a potentially novel mechanism by which Sirt6 activation alleviates cholestatic liver damage and fibrosis through regulating ERRγ. We observed that hepatic expression of Sirt6 is repressed, whereas hepatic expression of ERRγ is upregulated in murine cholestasis models. Hepatocyte-specific Sirt6-KO mice were more severely injured after a bile duct ligation (BDL) than WT mice, and adenoviral reexpression of Sirt6 reversed liver damage and fibrosis as demonstrated by biochemical and histological analyses. Mechanistically, Sirt6 deacetylated ERRγ, thereby destabilizing ERRγ and inhibiting its transcriptional activity. Elimination of hepatic ERRγ using Ad-shERRγ abolished the deleterious effects of Sirt6 deficiency, whereas ERRγ overexpression aggravated cholestatic liver injury. Administration of a Sirt6 deacetylase activator prevented BDL-induced liver damage and fibrosis. In patients with cholestasis, Sirt6 expression was decreased, whereas total ERRγ and acetylated ERRγ levels were increased, confirming negative regulation of ERRγ by Sirt6. Thus, Sirt6 activation represents a potentially novel therapeutic strategy for treating cholestatic liver injury.

Authors

Lihua Hao, In Hyuk Bang, Jie Wang, Yuancheng Mao, Jae Do Yang, Soon-Young Na, Jeong Kon Seo, Hueng-Sik Choi, Eun Ju Bae, Byung-Hyun Park

×

Figure 1

Hepatic expression of Sirt6 and ERRγ after experimental BDL or DDC feeding in mice.

Options: View larger image (or click on image) Download as PowerPoint
Hepatic expression of Sirt6 and ERRγ after experimental BDL or DDC feedi...
(A) Lysates were prepared from primary hepatocytes 10 days after BDL and sirtuin expression was determined by Western blot (n = 4). (B and C) After BDL, liver homogenates were subjected to quantitative PCR (n = 4) or Western blotting (n = 4). (D) Protein levels of Sirt6 and ERRγ were analyzed in mice fed a DDC diet (n = 4). Values are shown as mean ± SEM. Comparisons were made using paired 2-tailed Student’s t test (A and D) or 1-way ANOVA followed by Tukey’s multiple-comparisons test (B and C). *P < 0.05 and **P < 0.01 versus sham or control mice.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts